martes, 14 de junio de 2016

National Guideline Clearinghouse | Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.

National Guideline Clearinghouse | Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.

National Guideline Clearinghouse (NGC)

National Institute for Health and Care Excellence (NICE)
Guideline Title
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.
Bibliographic Source(s)
National Institute for Health and Care Excellence (NICE). Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. London (UK): National Institute for Health and Care Excellence (NICE); 2016 Jan 27. 44 p. (Technology appraisal guidance; no. 377). 
Guideline Status
This is the current release of the guideline.
This guideline meets NGC's 2013 (revised) inclusion criteria.

No hay comentarios:

Publicar un comentario